MedTrace Logo

A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)

NCT06412250 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-09-18

No results posted yet for this study

Summary

The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR and planned for an abbreviated (≤ 3 months) dual antiplatelet therapy (DAPT) regimen.

Conditions

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Translumina Therapeutics Pvt Ltd.

    lead INDUSTRY

Principal Investigators

  • Prof Adnan Kastrati · German Heart Centre Munich, Germany

  • Prof Azfar Zaman · Freeman Hospital, Newcastle, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2027-07-31
Completion
2027-11-30

Countries

  • India
  • Italy
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412250 on ClinicalTrials.gov